This technology establishes a long-lasting antioxidative and immunomodulatory platform using 20–30 nm CeO₂ with self-regenerating Ce³⁺/Ce⁴⁺ redox cycling. The platform scavenges ROS and inhibits NF-κB signaling. Animal studies demonstrate significant improvements in bladder pain and urinary frequency, as well as restoration of muscle strength and quantity in sarcopenia models. ISO 10993 safety validation and GMP manufacturing processes are completed, demonstrating commercialization potential.

This technology pioneers a therapeutic platform with self-regenerating Ce³⁺/Ce⁴⁺ redox cycling, enabling long-lasting ROS scavenging and simultaneous inhibition of NF-κB/MAPK inflammatory pathways. It overcomes the short-acting and easily depleted nature of conventional antioxidants. Animal models show improved cystitis-related pain and urinary frequency, restored muscle strength and fiber structure in sarcopenia, and strong disease-modifying potential.

This technology provides a long-acting antioxidative and immunomodulatory therapeutic platform for interstitial cystitis, sarcopenia, and other chronic inflammatory diseases. Compared with current short-acting analgesic and anti-inflammatory therapies, it offers disease-modifying and tissue-repair potential. With ISO 10993 safety validation and GMP manufacturing established, it supports commercialization through licensing, technology transfer, co-development, or startup formation.